|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sodium cantharidinate,a novel anti-pancreatic cancer agent that activates functional p53显示文摘Despite the use of many types of chemotherapies for pancreatic cancer, optimal efficacy has not been obtained so far. Pancreatic cancer shows a high incidence of TP53 mutations, inactivating its tumor suppressor activity. In this study, we identified sodium cantharidinate as a novel, potential anti-pancreatic cancer agent that activates p53 function. Sodium cantharidinate reduced the viability of pancreatic cancer cells, including the human primary pancreatic cancer cells, PANC-1, As PC-1, SW1990 and BXPC-3, in a dose-dependent manner. Sodium cantharidinate induced apoptosis and DNA damage of pancreatic cancer cells. Furthermore, proteome-wide sequencing analysis detected a marked perturbation in p53 signaling pathway on PANC-1 cells upon sodium cantharidinate. Consistent with the previous results, sodium cantharidinate treatment decreased Bcl-2 and mitochondrial cytochrome-c protein expression, as well as phosphorylation of MDM2;meanwhile, it increased the levels of cleaved-caspase-3,cleaved-caspase-9, cleaved-PARP, Bax, and phosphorylated p53, thus inducing the apoptosis of pancreatic cancer cells. The p53-activating effect of sodium cantharidinate was strongly abrogated by treatment with TP53-targeting sh RNA. Moreover, sodium cantharidinate inhibited neoplasm growth via the JAK2-STAT3 pathway, which was inhibited by sh RNA-TP53 and triggered by combination with gemcitabine. Combination therapy indicated that sodium cantharidinate and gemcitabine synergistically reduced ex vivo and in vivo growth of pancreatic neoplasm. Further docking studies revealed the different binding fates of sodium cantharidinate to activate wild-type p53 function. Thus, sodium cantharidinate could be a potential agent with promising anti-pancreatic cancer efficacy. | Xiaoxiao Liu Li Zhang Pyone Myat Thu Wenjian Min Peng Yang Ji Li Ping Li Xiaojun Xu | 2021 | Science China(Life Sciences)2021，64，8： | 5 |
| 2 | Safety,immunogenicity,and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates显示文摘Although antivirals are important tools to control severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection,effective vaccines are essential to control the current coronavirus disease 2019(COVID-19)pandemic.Plant-derived virus-like particle(VLP)vaccine candidates have previously demonstrated immunogenicity and efficacy against influenza.Here,we report the immunogenicity and protection induced in rhesus macaques by intramuscular injections of a VLP bearing a SARS-CoV-2 spike protein(CoVLP)vaccine candidate formulated with or without Adjuvant System 03(AS03)or cytidine-phospho-guanosine(CpG)1018.Although a single dose of the unadjuvanted CoVLP vaccine candidate stimulated humoral and cell-mediated immune responses,booster immunization(at 28 days after priming)and adjuvant administration significantly improved both responses,with higher immunogenicity and protection provided by the AS03-adjuvanted CoVLP.Fifteen micrograms of CoVLP adjuvanted with AS03 induced a polyfunctional interleukin-2(IL-2)-driven response and IL-4 expression in CD4 T cells.Animals were challenged by multiple routes(i.e.,intratracheal,intranasal,and ocular)with a total viral dose of 106 plaque-forming units of SARS-CoV-2.Lower viral replication in nasal swabs and bronchoalveolar lavage fluid(BALF)as well as fewer SARS-CoV-2-infected cells and immune cell infiltrates in the lungs concomitant with reduced levels of proinflammatory cytokines and chemotactic factors in the BALF were observed in animals immunized with the CoVLP adjuvanted with AS03.No clinical,pathologic,or virologic evidence of vaccineassociated enhanced disease was observed in vaccinated animals.The CoVLP adjuvanted with AS03 was therefore selected for vaccine development and clinical trials. | Stéphane Pillet Prabhu SArunachalam Guadalupe Andreani Nadia Golden Jane Fontenot Pyone Pyone Aye Katharina Röltgen Gabrielle Lehmicke Philipe Gobeil Charlotte Dubé Sonia Trépanier Nathalie Charland Marc-AndréD’Aoust Kasi Russell-Lodrigue Christopher Monjure Robert V.Blair Scott D.Boyd Rudolf P.Bohm Jay Rappaport François Villinger Nathalie Landry Bali Pulendran Brian J.Ward | 2022 | Cellular & Molecular Immunology2022，19，2： | 2 |
| 3 | Rib-sparing and internal mam- mary artery-preserving mierosurgical breast reconstruction with the free DIEP flap显示文摘 | Kim H Lira SY Pyon JK | 2013 | Plast Reconstr Surg2013，131，3： | 1 |
| 4 | Surgical treatment of angiosarcoma of the scalp with superficial parotidectomy显示文摘 | Lim SY Pyon JK Mun GH | | 0，，02： | 1 |
| 5 | Decision support system for service quality management using customer knowledge in public service organization 显示文摘 | Pyon C U Lee M J Park S C | 2009 | Expert Systems with Applications2009，36，4： | 1 |
| 6 | Reconstructive surgical treatment of tuberculosis abscess in the chest wall 显示文摘 | Lim SY Pyon JK Mun GH | 2010 | Ann Plast Surg2010，64，3： | 1 |
| 7 | Secondary revisions due to unfavourable results after microtia reconstruction 显示文摘 | LEE T S LIM S Y PYON J K | 2010 | J Plast Reconstr Aesthet Surg2010，63，6： | 1 |
| 8 | Expression of RUNX3 in skin cancers显示文摘 | Lee JH Pyon JK Kim DW | 2011 | Clin Exp Dermatol2011，36，7： | 1 |
| 9 | Positive affect, intertemporal choice, and levels of thinking: Increasing consumers' willingness to wait显示文摘 | Pyone J S and Isen A M | 2011 | Journal of Marketing Research2011，48，3： | 1 |
| 10 | Secondary revisions due to unfavourable results after microtia reconstruction显示文摘 | Lee TS Lim SY Pyon JK | 2010 | J Plast Reconstr Aesthet Surg2010，63，6： | 1 |
| 11 | Lung recruitment and breathing pattern during variable versus continuous flow nasal conti-nuous positive airway pressure in premature infant:an evaluation of three devices显示文摘 | Courtney SE Pyon KH Saslow JG | 2014 | Pediatrics2014，107，2： | 1 |
| 12 | Positive affect,intertemporal choice,and levels of thinking:Increasing consumers'willingness to wait显示文摘 | Pyone J.S A.M.Isen | | 0，，03： | 1 |
| 13 | The influence of pedicle length on the viability of twisted perforator flaps in rats 显示文摘 | Chang CH Lim SY Pyon JK | 2009 | J Reconstr Microsurg2009，25，9： | 1 |
| 14 | Lung recruitment and breathing pattern during variable versus continuous flow nasal continuous positive airway pressure in premature infants:an evaluation of three devices显示文摘 | Courtney SE Pyon KH Saslow JG | 2001 | Pediatrics2001，107，2： | 1 |
| 15 | Decision Support System for Service Qual- ity Management Using Customer Knowledge in Public Service Organization 显示文摘 | Chong Un Pyon Min Jung Lee Sang Chart Park | 2009 | Expert Sys- tems with Applications2009，36，： | 1 |
| 16 | Expression of RUNX3 in skincancers显示文摘 | Lee JH Pyon JK Kim DW | 2011 | Clin Exp Dermatol2011，36，7： | 1 |
| 17 | Work of breathing during constant-and-variable-flow nasal continuous positive airway pressure in pretenn neonates 显示文摘 | Pandit PB Courtney SE Pyon KH | 2001 | Pediatrics2001，108，3： | 1 |
| 18 | Lung recruitment and breathing pattern during variable versus continuous flow nasal continuous positive airway pressure in premature infant:an evaluation of three devices显示文摘 | Courtney SE Pyon KH Saslow JG | 2004 | Pediatrics2004，107，2： | 1 |
| 19 | Perforator-based Pacman flap in the plantar region显示文摘 | Kim H Pyon JK Lim SY | 2011 | J Foot Ankle Surg2011，50，6： | 1 |
| 20 | Finding research trend ofconvergence technology based on Korean R&D network显示文摘 | Jin J H Park S C Pyon C U | 2011 | Expert Systems with Applications2011，38，15： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员